Geron Reports Q1 2026 Earnings Call Details
Geron (GERN) reported Q1 2026 earnings call details, highlighting a 31% year-over-year increase in RYTELO net revenue to $51.8 million and a 9% year-over-year decline in operating expenses. The company also noted a 21% gross-to-net reduction, driven by expanded 340B participation and increased GPO contracting.
Topics: cash flow expenses financial performance pharmaceuticals revenue